glp-1 agonist gastric emptying medications safe to continue before surgery in patients with diabetes and obesity GLP-1 and Anesthesia: Considerations and

Neither timing has demonstrated superiority in clinical data

Tokyo, Japan: Takeda Pharmaceuticals, 130

In this study, participants taking orforglipron experienced an average A1C reduction of 2.1% and an average weight loss of 10.1 kilograms at 26 weeks, which was significantly greater than those in the placebo and dulaglutide groups

As with any medication, it's important to discuss with a healthcare provider whether a GLP-1 receptor agonist is a suitable option for managing diabetes

The 12mg group may have had different baseline compositions, or the additional weight loss at 12mg may have included a slightly higher proportion of lean tissue

reported that GLP-1R analogues enhance synaptic plasticity in area CA1 of the hippocampus (174)